Home Overview Press Room Blog Publications For Students about us

About California Policies & Human Biotechnology

California has been a pioneer in several aspects of policy on new biotechnologies, most notably with the passage in 2004 of Proposition 71, which established the California Institute for Regenerative Medicine (CIRM) and authorized to distribute and oversee $3 billion in public funds to support stem cell research and build research facilities over ten years.

The CIRM has been closely watched by other states and countries. It launched two experiments: the first an experiment in biomedical investigation; the second in its politics and policy. Never before has a state so generously funded an emerging scientific field. And never before has a state been faced with regulating and overseeing a field that combines promising medical research with significant social risks.

Before that, the California Advisory Committee on Human Cloning issued a report that led to a state ban on reproductive cloning. In 2003, a state agency blocked the sale of genetically modified fish as pets. In 2006, the state legislature passed a law providing protections for women who may provide eggs for cloning-based stem cell research.

California stem cell agency approves $30 million to fast-track clinical trialsby David JensenThe Sacramento BeeOctober 19th, 2016Dubbed the new “pitching machine,” CIRM on Wednesday completed creation of a $30 million effort to dramatically speed up FDA approval of stem cell therapies.
Scandals Waiting to Happen: Institutional Conflicts of Interest at California Stem Cell Agencyby Pete ShanksSeptember 8th, 2016StemCells Inc., which has received tens of millions of dollars from the state-funded stem cell agency, paid its president a hefty sum when he joined its board a week after resigning his position.
Victory: Eggs-for-Research Bill Dies in California Legislatureby Emily Galpern, Biopolitical Times guest contributorSeptember 8th, 2016A bill that would have expanded the commercial markets for human eggs, putting women’s health at risk, never made it to the Governor’s desk.
Stem Cell Company Paid $443,500 to Former Head of State Agency That Funds Researchby David JensenThe Sacramento BeeSeptember 1st, 2016Conflict-of-interest allegations have dogged the agency since it was created in 2004 by California voters to use state bond proceeds to finance stem cell research.
Public policy must address technology’s impact[citing CGS' Marcy Darnovsky]by John M. HeinThe Sacramento BeeAugust 13th, 2016“We need to develop habits of mind, or habits of social interaction, that will allow for some very robust public participation on the use of these powerful technologies,” says Marcy Darnovsky.
Booming demand, state protections attract commercial surrogate birthingby Kathy RobertsonSacramento BeeAugust 5th, 2016California has more surrogacy regulation than most states. But the founder of an agency comments, "Anybody in the whole world – even a felon – can open an agency. There is no licensing, no background check."
The Human Egg Business: More Media Coverage of California Cash-for-Eggs Legislation[citing CGS]by David JensenCalifornia Stem Cell ReportAugust 5th, 2016AB 2531, backed by the fertility industry, would remove caps on payments for egg retrieval, thus inducing women to gamble with their health.
Bill to expand market in women’s egg donations would undermine safeguards[citing CGS]by Deborah OrtizSacramento BeeAugust 4th, 2016Let’s not repeal a law that safeguards the health of women. We can support biomedical research without putting women’s health at risk.
NY Times: Fresh and Major Attention to Immunotherapy and Cancerby David JensenCalifornia Stem Cell ReportJuly 31st, 2016The New York Times unveiled a dramatic special report on gene therapy and immunotherapy to treat cancer.
Influential Scientific Journal Rips Effort to Loosen Stem Cell Research Rulesby David JensenCalifornia Stem Cell ReportJuly 5th, 2016Proposed treatments have not received FDA approval due to inefficacy and safety concerns.
Displaying 1-10 of 800  
Next >> 
Last Page » 
« Show Complete List » 


home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760